GSK:LON
GSK
1 770,83 GBX
arrow_upward
+1,19%(+20,83) 1 d.
12. okt., 18:17:16 GMT+1 · GBX
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: GSK…
Atvērt
1 755,00 GBX
Augsta
1 771,00 GBX
Zema
1 751,00 GBX
Tirgus kapitalizācija
94,36 mljrd.
Vid. apjoms
5,90 milj.
Apjoms
3,15 milj.
Dividende
3,84%
Ceturkšņa dividendes
17,00 GBX
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 13. aug.
Cenas/peļņas attiecība
15,01
Augstākā 52 ned.
2 282,00 GBX
Zemākā 52 ned.
1 592,00 GBX
Peļņa uz vienu akciju
1,18 GBX
Apgrozībā esošās akcijas
4,32 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
1 755,00 GBX
Augsta
1 771,00 GBX
Zema
1 751,00 GBX
Tirgus kapitalizācija
94,36 mljrd.
Vid. apjoms
5,90 milj.
Apjoms
3,15 milj.
Dividende
3,84%
Ceturkšņa dividendes
17,00 GBX
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 13. aug.
Cenas/peļņas attiecība
15,01
Augstākā 52 ned.
2 282,00 GBX
Zemākā 52 ned.
1 592,00 GBX
Peļņa uz vienu akciju
1,18 GBX
Apgrozībā esošās akcijas
4,32 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Patch
·
pirms 1 stundas
Pharma Giant GSK To Expand In Upper Merion, Investing $800 Million
TipRanks
·
pirms 3 stundām
GSK Executives Reinvest Dividends in Routine Share Acquisitions
Endpoints News
·
pirms 4 stundām
GSK to invest $800M for new R&D, manufacturing hub in Pennsylvania
ad-hoc-news.de
·
pirms 6 stundām
GSK stock costs EUR 20.89 with USD 93.2 billion market value
Profils
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Par “GSK”
ĢenerāldirektorsEmma Walmsley | Emma Walmsley
Darbinieki66,8 tūkst.
Dibināšanas datums2000. gada 27. dec.
Galvenais birojs-
Sektors-
Tīmekļa vietnegsk.com